Matches in Wikidata for { <http://www.wikidata.org/entity/Q64217535> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q64217535 description "clinical trial" @default.
- Q64217535 description "ensayu clínicu" @default.
- Q64217535 description "klinisch onderzoek" @default.
- Q64217535 description "клінічне випробування" @default.
- Q64217535 description "կլինիկական փորձարկում" @default.
- Q64217535 name "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study" @default.
- Q64217535 type Item @default.
- Q64217535 label "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study" @default.
- Q64217535 prefLabel "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study" @default.
- Q64217535 P1132 Q64217535-F4576EA0-3392-44E5-9E9D-C12088DD745A @default.
- Q64217535 P131 Q64217535-ABBBBD23-B490-4AC6-A5C3-ABE29083C337 @default.
- Q64217535 P1476 Q64217535-C0BF8176-B967-4FA7-B980-5BABCCE633C8 @default.
- Q64217535 P17 Q64217535-1173B4D2-E5B7-4C0C-98EF-8EC912702C29 @default.
- Q64217535 P17 Q64217535-13168C3E-EFEA-4ED0-A1D8-67D0224174E8 @default.
- Q64217535 P17 Q64217535-38857F7B-B790-495D-9966-F42FF3FBB94A @default.
- Q64217535 P17 Q64217535-6B943CD1-0AFC-4C29-8DC1-54C76DEEE06C @default.
- Q64217535 P17 Q64217535-A694E0A2-ACF2-4AC7-8E41-9281AB7554DB @default.
- Q64217535 P17 Q64217535-B3B2DCFE-686C-4AB7-9C50-60EEA67DBA72 @default.
- Q64217535 P17 Q64217535-C9ED9348-8390-475B-9B88-B8230ECA0D08 @default.
- Q64217535 P17 Q64217535-ED12BA13-B741-4016-AECD-2C676053B8AF @default.
- Q64217535 P17 Q64217535-F5F9FB83-B5A5-4D9A-BB85-08C549AA552C @default.
- Q64217535 P17 Q64217535-F924FB99-3872-4A1E-A7A2-BA6D86D1338E @default.
- Q64217535 P2899 Q64217535-35BD4245-8924-40F5-BD06-68605A50B33F @default.
- Q64217535 P3098 Q64217535-5BA3BD13-5354-4FF2-AE00-27F1BD98ADA2 @default.
- Q64217535 P31 Q64217535-A78924C3-D45D-4DFF-8FF8-7E7BC2C4449A @default.
- Q64217535 P580 Q64217535-E336766C-508C-477F-84FA-41AF27626C24 @default.
- Q64217535 P582 Q64217535-A38A1498-955B-442E-A4CC-0EBA8AD7547E @default.
- Q64217535 P6099 Q64217535-93ED6316-5BCD-4FBA-B646-9BCC14284B1C @default.
- Q64217535 P6153 Q64217535-167A4A2C-79F1-43C7-BE58-09209AEDEE24 @default.
- Q64217535 P6153 Q64217535-6B7780EB-AC9F-4774-A672-B3EAFD90936E @default.
- Q64217535 P8363 Q64217535-9884FDFC-4D77-4667-834F-A71259724926 @default.
- Q64217535 P859 Q64217535-FE3345F6-4AF2-4D30-AC8A-E6E71EC59781 @default.
- Q64217535 P1132 "+150" @default.
- Q64217535 P131 Q8646 @default.
- Q64217535 P1476 "An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib" @default.
- Q64217535 P17 Q142 @default.
- Q64217535 P17 Q17 @default.
- Q64217535 P17 Q183 @default.
- Q64217535 P17 Q29 @default.
- Q64217535 P17 Q30 @default.
- Q64217535 P17 Q31 @default.
- Q64217535 P17 Q334 @default.
- Q64217535 P17 Q38 @default.
- Q64217535 P17 Q408 @default.
- Q64217535 P17 Q865 @default.
- Q64217535 P2899 "+18" @default.
- Q64217535 P3098 "NCT02584933" @default.
- Q64217535 P31 Q30612 @default.
- Q64217535 P580 "2015-12-11T00:00:00Z" @default.
- Q64217535 P582 "2020-12-14T00:00:00Z" @default.
- Q64217535 P6099 Q42825046 @default.
- Q64217535 P6153 Q1057447 @default.
- Q64217535 P6153 Q507154 @default.
- Q64217535 P8363 Q78089383 @default.
- Q64217535 P859 Q507154 @default.